The risk for bullous pemphigoid was higher in men with diabetes using DPP inhibitors than in women (OR, 1.91 vs 1.24). Bullous pemphigoid risk was highest in men with diabetes who were using ...

Results showed that DPP-4 inhibitors yielded 0.42 cases of bullous pemphigoid per 1,000 person-years compared with 0.31 cases per 1,000 person-years for sulfonylureas (HR = 1.42; 95% CI, 1.17-1.72).

Kawaguchi Y, Shimauchi R, Nishibori N et al. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus cases [published ...

Specifically, patients age 65 and older on a DPP-4 inhibitor saw a 62% higher risk for developing bullous pemphigoid compared with like-age sulfonylurea users (incidence rates 0.79 vs 0.49, HR 1. ...

1 Dipeptidyl peptidase-4 inhibitors are commonly used to treat diabetes, and are associated with development of noninflammatory bullous pemphigoid, with an incidence of 0.42 per 1000 person-years.1 – ...

They cautioned that cases of bullous pemphigoid have recently been reported in patients after beginning treatment with dipeptidyl peptidase 4 inhibitors such as sitagliptin (Januvia) and ...

What disorders should be included in the differential diagnosis of a 91-year-old white woman with acute onset of bullous-appearing lesions on the tips of her index, middle, ring, and fifth fingers ...

Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions.

Bullous Pemphigoid Drug Pipeline Research Report 2023: Comprehensive Insights on 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com November 10, 2023 09:08 AM Eastern Standard Time.

People with bullous pemphigoid are typically given topical or oral steroids to treat the “tense blisters” that show up on the arms, legs, lower body and occasionally in the mouth.

Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions.